Enovis Corporation
NYSE:ENOVMedical - Devices
+$0.73 today
- Market cap
- $1.56B
- Beta
- 1.49
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$20.02
Volume 0.88M
Average 0.99M
ENOV EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Enovis CorporationNYSE: ENOV
EPS (Diluted) · Q1 FY2026 · quarter ended Apr 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.15, compared with -$0.99 a year earlier. Trailing-twelve-month EPS (Diluted) was -$20.02.
Context
- EPS (Diluted) grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 7 analysts of $3.7 (+117.7%) for the fiscal year ending Dec 2026, a step up from the -39.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterApr 2026
- -$0.15+98.4% QoQ
- Last fiscal yearDec 2025
- -$20.86-39.7% YoY
- LTMApr 2026
- -$20.02-43.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +84.8% | +232.3% | +147.5 pp |
| 1 year | -39.7% | +117.7% | +157.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (20.86) USD
- Year-over-year change
- -39.7%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (20.86) | -39.7% |
| FY2024 | 2024-12-31 | (14.93) | -2347.5% |
| FY2023 | 2023-12-31 | (0.61) | -117.9% |
| FY2022 | 2022-12-31 | (0.28) | +86.1% |
| FY2021 | 2021-12-31 | (2.02) | — |
EPS (Diluted) vs competitors
How ENOV compares with its peers on the latest reported figures
- ENOV's LTM Apr 2026 EPS (Diluted) of -$20.02 is the lowest of the 16 companies compared; the peer median is $2.14.
- Its year-over-year change of -43.5% is the 13th highest of 16, against a peer median of +3.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $11.46 | +23.2% | +10.7% | |
| LTM Jul 2026 | $9.3 | +3.6% | -5.8% | |
| LTM Jun 2026 | $6.95 | +12.3% | -6.0% | |
| LTM Jul 2026 | $5.1 | -19.8% | +11.7% | |
| LTM Sep 2026 | $4.45 | +45.0% | -6.7% | |
| LTM Jul 2026 | $3.85 | +26.2% | +9.9% | |
| LTM Jun 2026 | $2.36 | +19.8% | +67.5% | |
| LTM Jul 2026 | $2.14 | +105.8% | -21.7% | |
| LTM Jun 2026 | $2.04 | -49.0% | -42.1% | |
| LTM Feb 2026 | $1.6 | -5.3% | +87.0% | |
| LTM Mar 2026 | $1.33 | -22.7% | -14.4% | |
| LTM Mar 2026 | $1.12 | +0.9% | +219.3% | |
| LTM Mar 2026 | $0.21 | -73.7% | -34.1% | |
| LTM Apr 2026 | -$1.95 | +35.0% | — | |
| LTM Jul 2026 | -$9.27 | -217.9% | — | |
| LTM Apr 2026 | -$20.02 | -43.5% | — | |
| Peer median (excluding ENOV) | $2.14 | +3.6% | -5.8% | |
Competitors are the stored peer set for ENOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.43B | 1.56B | 1.71B | 2.11B | 2.25B |
| Cost of Revenue | 648.51M | 693.72M | 716.42M | 926.87M | 902.79M |
| Gross Profit | 777.68M | 869.38M | 990.78M | 1.18B | 1.35B |
| Gross Margin | 54.5% | 55.6% | 58.0% | 56.0% | 59.8% |
| Research & Development | 49.09M | 60.83M | 75.33M | 91.3M | 120.33M |
| Selling, General & Admin | 665.78M | 772.91M | 830.31M | 939.36M | 1.07B |
| Operating Expenses | 840.47M | 940.56M | 1.06B | 1.96B | 1.36B |
| Depreciation & Amortization | 262.92M | 219.71M | 217.11M | 284.8M | 294.38M |
| EBITDA | 170.25M | 241.69M | 169.73M | (481.03M) | (830.22M) |
| EBITDA Margin | 11.9% | 15.5% | 9.9% | -22.8% | -36.9% |
| Operating Income | (62.8M) | (71.18M) | (65.71M) | (775.72M) | (18.87M) |
| Operating Margin | -4.4% | -4.6% | -3.8% | -36.8% | -0.8% |
| Interest Income | 0 | 200K | 0 | 0 | 0 |
| Interest Expense | 29.11M | 24.95M | 19.75M | 57.1M | 34.82M |
| Other Income / Expenses | (58.98M) | 69.11M | (1.42M) | (47.21M) | (1.14B) |
| Income Before Tax | (121.78M) | (2.07M) | (67.13M) | (822.92M) | (1.16B) |
| Pre-Tax Margin | -8.5% | -0.1% | -3.9% | -39.0% | -51.6% |
| Income Tax Expense | (19.53M) | 36.12M | (13.29M) | 4.49M | 22.29M |
| Net Income | 71.66M | (13.29M) | (33.26M) | (825.49M) | (1.18B) |
| Net Margin | 5.0% | -0.9% | -1.9% | -39.2% | -52.7% |
| EPS (Basic) | (2.02) | (0.28) | (0.61) | (14.93) | (20.86) |
| EPS (Diluted) | (2.02) | (0.28) | (0.61) | (14.93) | (20.86) |
| Weighted Avg Shares | 51.14M | 54.07M | 54.53M | 55.28M | 56.79M |
| Weighted Avg Shares (Diluted) | 51.14M | 54.07M | 54.49M | 55.28M | 56.79M |
Enovis Corporation
NYSE:ENOV
Intrinsic Alpha fair value
Locked
Current Price
$27.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.